EGFR and non-small cell lung carcinoma: Although epithelial growth factor receptor (EGFR) mutation-positive advanced/recurrence NSCLC can receive EGFR tyrosine kinase inhibitors (TKIs) as a promising targeted treatment; their 5-year relative survival rate is just 5% after treatment [1].